Published in Bioorg Med Chem Lett on March 28, 2014
Enhanced semiempirical QM methods for biomolecular interactions. Comput Struct Biotechnol J (2015) 0.79
The Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 Deficiency. Plant Physiol (2016) 0.76
Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. FEBS J (2015) 0.75
VMD: visual molecular dynamics. J Mol Graph (1996) 117.02
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr (2011) 39.32
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2004) 23.86
Climbing the density functional ladder: nonempirical meta-generalized gradient approximation designed for molecules and solids. Phys Rev Lett (2003) 3.63
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging (2012) 3.22
Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters. J Mol Model (2012) 2.82
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med (1999) 1.79
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem (2010) 1.51
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging (2003) 1.49
Density functional theory augmented with an empirical dispersion term. Interaction energies and geometries of 80 noncovalent complexes compared with ab initio quantum mechanics calculations. J Comput Chem (2007) 1.46
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem (2008) 1.39
Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem (2012) 1.34
Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem (2001) 1.32
A quantum mechanics-based scoring function: study of zinc ion-mediated ligand binding. J Am Chem Soc (2004) 1.15
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem (2007) 1.08
Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci (2007) 1.08
NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotrauma (2005) 1.06
Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol (2008) 1.01
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00
Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem (2007) 0.98
A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.98
Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr Med Chem (2012) 0.97
The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. Curr Med Chem (2012) 0.95
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. Prostate (2009) 0.93
Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J Med Chem (2000) 0.91
Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry (2009) 0.90
Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. FEBS J (2007) 0.89
Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme. Curr Med Chem (2012) 0.87
Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. Eur J Biochem (2004) 0.87
ProstaScint(R) Scan: Contemporary Use in Clinical Practice. Rev Urol (2004) 0.86
Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. Curr Med Chem (2012) 0.86
Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. Brain Res (2011) 0.86
Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. J Med Chem (2011) 0.84
NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. Brain Res (2012) 0.79
Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: Synthesis and structural characterization. Bioorg Med Chem Lett (2015) 0.75